Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Similar articles for PubMed (Select 22987054)


Effects of valsartan on cardiovascular morbidity and mortality in high-risk hypertensive patients with new-onset diabetes mellitus.

Kimura S, Sawada T, Shiraishi J, Yamada H, Matsubara H; KYOTO HEART Study Group.

Circ J. 2012. pii: DN/JST.JSTAGE/circj/CJ-12-0387. Epub 2012 Sep 12. Retraction in: Shimokawa H. Circ J. 2013;77(2):552a.


Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).

Shiraishi J, Sawada T, Koide M, Yamada H, Matsubara H; Kyoto Heart Study Group.

Am J Cardiol. 2012 May 1;109(9):1308-14. doi: 10.1016/j.amjcard.2011.12.025. Epub 2012 Feb 9.


Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study.

Shiraishi J, Sawada T, Kimura S, Yamada H, Matsubara H; KYOTO HEART Study Group.

Circ J. 2011;75(4):806-14. Epub 2011 Mar 19. Retraction in: Shimokawa H. Circ J. 2013;77(2):552b.


Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A; VALUE Trial Investigators.

J Hypertens. 2006 Jul;24(7):1405-12.


Valsartan: more than a decade of experience.

Black HR, Bailey J, Zappe D, Samuel R.

Drugs. 2009;69(17):2393-414. doi: 10.2165/11319460-000000000-00000. Review.


Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.

Circ Heart Fail. 2008 May;1(1):34-42. doi: 10.1161/CIRCHEARTFAILURE.107.736975.


Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.

Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.

Blood Press. 2008;17(3):170-7. doi: 10.1080/08037050802169644.


Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.

Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL.

Am J Cardiovasc Drugs. 2011 Oct 1;11(5):327-33. doi: 10.2165/11591970-000000000-00000.


Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.


Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.

Petrella R, Michailidis P.

Clin Ther. 2011 Sep;33(9):1190-203. doi: 10.1016/j.clinthera.2011.08.008. Epub 2011 Sep 1.


A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.

Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P.

J Am Coll Cardiol. 2013 Jan 15;61(2):131-42. doi: 10.1016/j.jacc.2012.10.011. Epub 2012 Dec 5.


The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.

Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR.

Hypertension. 2006 Sep;48(3):385-91. Epub 2006 Jul 24.


Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.

Aksnes TA, Kjeldsen SE, Rostrup M, Störset O, Hua TA, Julius S.

J Hum Hypertens. 2008 Aug;22(8):520-7. doi: 10.1038/jhh.2008.41. Epub 2008 May 29.


Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.

Mizuta Y, Kai H, Mizoguchi M, Osada K, Tahara N, Nakaura H, Kuwahara F, Imaizumi T; Valsartan Diastolic Function Improvement Study Investigators.

Hypertens Res. 2008 Oct;31(10):1835-42. doi: 10.1291/hypres.31.1835.


Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.

Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN; Val-HeFT Investigators (Valsartan Heart Failure Trial).

J Am Coll Cardiol. 2002 Oct 16;40(8):1414-21.


Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

Okin PM.

J Electrocardiol. 2009 Nov-Dec;42(6):584-8. doi: 10.1016/j.jelectrocard.2009.06.020. Epub 2009 Jul 24.


Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.

Sawada T, Yamada H, Shiraishi J, Kimura S, Matsubara H.

Clin Exp Hypertens. 2012;34(2):153-9. doi: 10.3109/10641963.2011.577493. Epub 2011 Oct 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk